VEVYE Drug Patent Profile
✉ Email this page to a colleague
When do Vevye patents expire, and what generic alternatives are available?
Vevye is a drug marketed by Harrow Eye and is included in one NDA. There are four patents protecting this drug.
This drug has eighty-one patent family members in nineteen countries.
The generic ingredient in VEVYE is cyclosporine. There are eighteen drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the cyclosporine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Vevye
A generic version of VEVYE was approved as cyclosporine by HIKMA on October 29th, 1999.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for VEVYE?
- What are the global sales for VEVYE?
- What is Average Wholesale Price for VEVYE?
Summary for VEVYE
International Patents: | 81 |
US Patents: | 4 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for VEVYE |
What excipients (inactive ingredients) are in VEVYE? | VEVYE excipients list |
DailyMed Link: | VEVYE at DailyMed |
![VEVYE drug patent expirations Drug patent expirations by year for VEVYE](/p/graph/s/t/VEVYE-patent-expirations.png)
![Drug Prices for VEVYE](/p/graph/drug-price/VEVYE.png)
Pharmacology for VEVYE
Drug Class | Calcineurin Inhibitor Immunosuppressant |
Mechanism of Action | Calcineurin Inhibitors Cytochrome P450 3A4 Inhibitors P-Glycoprotein Inhibitors |
US Patents and Regulatory Information for VEVYE
VEVYE is protected by four US patents and one FDA Regulatory Exclusivity.
Patents protecting VEVYE
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF THE SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF DRY EYE DISEASE (DED)
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
FDA Regulatory Exclusivity protecting VEVYE
NEW PRODUCT
Exclusivity Expiration: ⤷ Sign Up
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Harrow Eye | VEVYE | cyclosporine | SOLUTION;OPHTHALMIC | 217469-001 | May 30, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Harrow Eye | VEVYE | cyclosporine | SOLUTION;OPHTHALMIC | 217469-001 | May 30, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Harrow Eye | VEVYE | cyclosporine | SOLUTION;OPHTHALMIC | 217469-001 | May 30, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for VEVYE
See the table below for patents covering VEVYE around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
World Intellectual Property Organization (WIPO) | 2017055453 | ⤷ Sign Up | |
Denmark | 2512515 | ⤷ Sign Up | |
Denmark | 3722274 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for VEVYE
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2049079 | LUC00006 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: CYCLOSPORINE (GOUTTES OCULAIRES SOUS FORME D'EMULSION); AUTHORISATION NUMBER AND DATE: EU/1/15/990 20150323 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |